Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | CDK4 | P11802 | 3/20 | 0.52 |
| ▸ | CCND1 | P24385 | 3/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.51 |
| ▸ | GOT1 | P17174 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25368472 | 0.83 | LMNA (0.48) | MAPTSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL25432990 | 0.79 | CSNK2A1 (0.47) | MEN1KMT2A | |
| SCHEMBL25371432 | 0.78 | NAMPT (0.49) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL25368280 | 0.77 | DHX9 (0.53) | MEN1KMT2AMAPTHTTSMN1; SMN2 | |
| SCHEMBL25369891 | 0.77 | DHX9 (0.44) | MEN1KMT2AMAPTHTTSMN1; SMN2 | |
| SCHEMBL25368167 | 0.77 | ALDH1A1 (0.50) | MEN1KMT2AHTTSMN1; SMN2LMNA | |
| SCHEMBL25370694 | 0.75 | SMN1; SMN2 (0.49) | MEN1KMT2AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL25368505 | 0.74 | DHX9 (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL25367270 | 0.74 | MAPK14 (0.47) | MAPTHTTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL25367459 | 0.74 | ALDH1A1 (0.51) | MEN1KMT2AMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4479380-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | MEN1 3047/4885KMT2A 2280/4885MAPT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.